“A costly failure” and “a fiasco” are just two of the epithets that have been used to describe the first-ever risk-sharing scheme in the UK to evaluate the long-term cost-effectiveness of two multiple sclerosis therapies, β-interferon and glatiramer acetate...
Please login to read the full article.
